{"id":"4447ce7f-d0ed-5475-bfec-755a50f4912c","stable_key":"773f772e-bf8e-5e52-a2a2-6dd694d67f5d:bromelain-oral-absorption","predicate":"appears_intact_in","statement":"After oral bromelain in 19 healthy men, immunoreactive bromelain with retained proteolytic activity was detected in plasma; the estimated half-life was 6-9 hours.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"7420da6c-c4a6-5810-be92-ba3b79c4317a","mechanism_event_label":"After oral bromelain in 19 healthy men, immunoreactive bromelain with retained proteolytic activity was detected in plasma; the estimated half-life was 6-9 hours.","subject":{"id":"6a3990e6-85af-58c7-8087-8a251db842fa","slug":"bromelain","display_name":"Bromelain","entity_type_key":"peptide"},"object":{"id":"66440111-f3a2-50f5-92b4-c968c9bf5251","slug":"human-plasma-intact-bromelain","display_name":"Intact, immunoreactive bromelain in human plasma","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"7420da6c-c4a6-5810-be92-ba3b79c4317a","stable_key":"773f772e-bf8e-5e52-a2a2-6dd694d67f5d:bromelain-oral-absorption-event","event_type":"observed_relationship","label":"After oral bromelain in 19 healthy men, immunoreactive bromelain with retained proteolytic activity was detected in plasma; the estimated half-life was 6-9 hours.","description":"After oral bromelain in 19 healthy men, immunoreactive bromelain with retained proteolytic activity was detected in plasma; the estimated half-life was 6-9 hours.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6a3990e6-85af-58c7-8087-8a251db842fa","slug":"bromelain","display_name":"Bromelain","entity_type_key":"peptide"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"66440111-f3a2-50f5-92b4-c968c9bf5251","slug":"human-plasma-intact-bromelain","display_name":"Intact, immunoreactive bromelain in human plasma","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Oral multidosing up to 3 g/day","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"Plasma sampling across 3-51 hours","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Nineteen healthy adult men","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Only a small absorbed fraction was detected; immunoreactivity and partial activity do not establish a free therapeutic plasma concentration.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Bromelain chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings.","comparator":null,"unit":null,"notes":"","entity":{"slug":"bromelain","display_name":"Bromelain","entity_type_key":"peptide"}},{"dimension":"organism","value_text":"Nineteen healthy adult men","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"After oral bromelain in 19 healthy men, immunoreactive bromelain with retained proteolytic activity was detected in plasma; the estimated half-life was 6-9 hours.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. (1997). https://pubmed.ncbi.nlm.nih.gov/9252520/ DOI: 10.1152/ajpgi.1997.273.1.G139","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Plasma immunoassay, immunoprecipitation and proteolytic activity","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"33a01134-b78d-5a94-af44-d3f5298dd17d","evidence_kind":"source_excerpt","locator":"Lines 11-20","start_line":11,"end_line":20,"excerpt":"## bromelain-oral-absorption\nAfter oral bromelain in 19 healthy men, immunoreactive bromelain with retained proteolytic activity was detected in plasma; the estimated half-life was 6-9 hours.\nModel/species: Nineteen healthy adult men\nTissue/system: Plasma immunoassay, immunoprecipitation and proteolytic activity\nExposure: Oral multidosing up to 3 g/day\nRoute: Oral\nDuration: Plasma sampling across 3-51 hours\nLimits: Only a small absorbed fraction was detected; immunoreactivity and partial activity do not establish a free therapeutic plasma concentration.\nPrimary reference: Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. (1997). https://pubmed.ncbi.nlm.nih.gov/9252520/ DOI: 10.1152/ajpgi.1997.273.1.G139\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"Nineteen healthy adult men","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact original curation span with primary citation; not a publisher quotation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"9d363b4e-f438-5664-9d74-99c2e359391d","stable_key":"import-773f772e-bf8e-5e52-a2a2-6dd694d67f5d","title":"Bromelain: mechanism of action and interactions (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text.","file_path":"","sha256":"b328dbb8082bea612bb2c40d6ff41fa670f6e62f714bd014c90627fcab86e95b","revision_id":"1c10d22e-ecdf-56ef-b820-bb21182a9577","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}